- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Coldrif Syrup banned in Maharashtra after child deaths

Mumbai: In a sweeping move to protect public health, the Maharashtra Food and Drugs Administration (FDA) has ordered to immediately stop the sale, distribution, and use of Coldrif Syrup across the state, following alarming reports of toxic adulteration linked to child deaths in Madhya Pradesh and Rajasthan.
Late Sunday night, State Drug Controller DR Gahane issued a statement alerting all licensees and the public to immediately freeze any stock of Coldrif Syrup (Phenylephrine Hydrochloride and Chlorpheniramine Maleate), Batch No. SR-13, manufactured by Sresan Pharma, Tamil Nadu.
The batch in question (Mfg: May 2025, Exp: April 2027) has been allegedly contaminated with Diethylene Glycol (DEG), a poisonous substance, the statement said.
As per IANS, Gahane said, “In view of this, all the licensees and public are hereby instructed to immediately stop sale/distribution/use of Coldrif Syrup, Batch No. SR-13, if anybody is in possession, and report it to the local Drugs Control Authorities without delay,”
The public can report possession of the drug directly to the FDA through the toll-free number 1800222365 and mobile phone number 9892832289 or via email to jchq.fda-mah@nic.in, the FDA statement added.
“The Maharashtra FDA officials are coordinating with the Drug Control Authorities of Tamil Nadu, the manufacturer's location, to trace the distribution of the affected batch within Maharashtra. All Drugs Inspectors and Assistant Commissioners have received instructions to alert retailers, wholesalers, and hospitals to freeze existing stocks immediately,” it said.
The state FDA said that it is taking necessary measures in this regard and appealed to the people to exercise caution to prevent any further risk to life.
The Maharashtra FDA's action aligns with a prior advisory from the Centre, which on Sunday urged states and Union Territories to ensure rational use of cough syrups, particularly among children, noting that most coughs are self-limiting.
The Centre urged states and UTs to strengthen surveillance, ensure timely reporting from all health facilities, widely promote the IDSP-IHIP community reporting tool, and enhance inter-state coordination for early reporting and joint action.
The Centre also emphasised strict compliance with the Revised Schedule by all drug manufacturers and urged states and UTs to conduct a thorough identification of non-compliant units and take strict action against them.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751